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Objectives Our goal was to compare the safety and initial efficacy of AZD6140, the first reversible oral adenosine diphos-
phate receptor antagonist, with clopidogrel in patients with non–ST-segment elevation acute coronary syndromes
(NSTE-ACS).
Background AZD6140 achieves higher mean levels of platelet inhibition than clopidogrel in patients with stable coronary ar-
tery disease.
Methods A total of 990 patients with NSTE-ACS, treated with aspirin and standard therapy for ACS, were randomized in a
1:1:1 double-blind fashion to receive either twice-daily AZD6140 90 mg, AZD6140 180 mg, or clopidogrel
300-mg loading dose plus 75 mg once daily for up to 12 weeks.
Results The primary end point, the Kaplan-Meier rate of major or minor bleeding through 4 weeks, was 8.1% in the clo-
pidogrel group, 9.8% in the AZD6140 90-mg group, and 8.0% in the AZD6140 180-mg group (p  0.43 and p 
0.96, respectively, vs. clopidogrel); the major bleeding rates were 6.9%, 7.1%, and 5.1%, respectively (p  0.91
and p  0.35, respectively, vs. clopidogrel). Although not statistically significant, favorable trends were seen in
the Kaplan-Meier rates of myocardial infarction (MI) over the entire study period (MI: 5.6%, 3.8%, and 2.5%, re-
spectively; p  0.41 and p  0.06, respectively, vs. clopidogrel). In a post-hoc analysis of continuous electrocar-
diograms, mostly asymptomatic ventricular pauses 2.5 s were more common, especially in the AZD6140
180-mg group (4.3%, 5.5%, and 9.9%, respectively; p  0.58 and p  0.01, respectively, vs. clopidogrel).
Conclusions This initial experience with AZD6140 in patients with ACS showed no difference in major bleeding but an in-
crease in minor bleeding at the higher dose with encouraging results on the secondary end point of MI. This
agent is currently being studied in a large outcomes trial in 18,000 patients with ACS. (J Am Coll Cardiol
2007;50:1844–51) © 2007 by the American College of Cardiology Foundation
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November 6, 2007:1844–51 The DISPERSE-2 Trialntiplatelet therapy with aspirin, thienopyridines (e.g.,
lopidogrel), or their combination has resulted in major
eductions in cardiovascular events (1–6). This latter class
nhibits platelet activation and aggregation by blocking the
2Y12 receptor, 1 of 2 adenosine diphosphate (ADP)
eceptors on platelets (7). However, clopidogrel has several
imitations: it is a pro-drug that requires hepatic conversion,
eading to delay in onset of action, and there is wide interin-
ividual variability in levels of platelet inhibition, with up to
ne-third of patients exhibiting minimal platelet inhibition
often referred to as “clopidogrel nonresponders”) (8–10).
t steady state, clopidogrel achieves only 30% to 40% mean
nhibition of platelet aggregation response to ADP, and its
ctive metabolite binds irreversibly to P2Y12 receptors, such
hat recovery of platelet function is precluded.
AZD6140 is the first reversible oral P2Y12 receptor
ntagonist in a new chemical class of antiplatelet agents
ermed cyclopentyl-triazolo-pyrimidines with a half-life of
pproximately 12 h (11,12). Distinct from the thienopyri-
ines, this agent does not require metabolic conversion to an
ctive form; it binds directly to the P2Y12 receptor, and it
an more completely inhibit the sustained aggregation
esponse to ADP. A study in patients with stable athero-
clerosis found a dose-dependent increase in the level of
nhibition with AZD6140, with levels being significantly
igher than those achieved with clopidogrel (12). The
ISPERSE (Dose confIrmation Study assessing anti-
latelet Effects of AZD6140 vs. clopidogRel in non–ST-
egment Elevation myocardial infarction)-2 trial was a
andomized, double-blind, double-dummy trial conducted
o assess the safety, tolerability, and initial efficacy of
ZD6140 plus aspirin in comparison with clopidogrel plus
spirin in patients with non–ST-segment elevation (NSTE)
cute coronary syndromes (ACS).
ethods
atients. Between October 3, 2004 and April 23, 2005,
atients with NSTE-ACS were entered into the trial from
52 participating sites in 14 countries (Online Appendix 1).
he study protocol was approved by the relevant institu-
ional review boards, and written informed consent was
btained from all patients before the initiation of trial
rocedures.
Detailed entry criteria are in Online Appendix 2. Briefly,
atients were eligible if they were hospitalized for NSTE-
CS within the preceding 48 h, experienced ischemic
ymptoms of 10 min duration at rest, with either bio-
hemical marker evidence of myocardial infarction (MI) or
lectrocardiographic evidence of ischemia.
tudy protocol. Patients received standard medical (anti-
schemic and antithrombotic) and interventional treatment
or ACS, including aspirin at an initial dose of up to 325 mg
ollowed by 75 to 100 mg daily with or without a glyco-
rotein IIb/IIIa inhibitor. Patients who had received clopi-
ogrel before randomization were permitted in the study, sut open-label clopidogrel was
iscontinued after randomization
nd replaced with study drug.
Eligible patients were ran-
omized in a 1:1:1 double-blind
ashion to receive AZD6140 90
g twice daily, AZD6140 180
g twice daily, or clopidogrel
00 mg followed by 75 mg once
aily for up to 3 months. Patients
n the AZD6140 group were
ubrandomized to receive or not
eceive an initial loading dose of
70 mg. Patients were scheduled
o receive 1, 2, or 3 months of
tudy drug, depending on when
uring the trial period they were
nrolled. For patients undergoing percutaneous coronary
ntervention (PCI) within 48 h post-randomization, an
dditional 300 mg of clopidogrel study drug or placebo
clopidogrel for patients in the clopidogrel group or placebo
or patients in the AZD6140 group) could be administered
t the discretion of the treating physician. Patients returned
onthly for follow-up visits, and were contacted by tele-
hone 7 days after stopping study drug for evaluation of any
dverse events.
The primary objective was to assess the safety and
olerability of the different doses of AZD6140 plus aspirin,
ersus clopidogrel plus aspirin, in patients with NSTE-ACS
y evaluating total bleeding events (major plus minor
leeding, but excluding minimal bleeds as adjudicated by
he Independent Clinical Adjudication Committee) ob-
erved within the first 4 weeks of treatment (see Online
ppendix 2 for definitions). Additional objectives of the
rial were to assess: 1) individual and composite incidence of
I (including silent MI), death, stroke, and severe recur-
ent ischemia; and 2) incidence of recurrent ischemia with
ZD6140 plus aspirin and clopidogrel plus aspirin, using
otal duration of ischemia as detected by continuous Holter
lectrocardiogram monitoring (LifeCard CF, DelMar
eynolds, Irvine, California) during the first 4 to 7 days
fter randomization.
tatistical analyses. Statistical analyses were performed
sing SAS version 8.1 (SAS Institute, Inc., Cary, North
arolina), with details provided in Online Appendix 2.
n independent data safety monitoring board comprising
linical experts and a statistician monitored safety data on
n ongoing basis to ensure that patient safety was
aintained. Comparisons between AZD6140 and clopi-
ogrel were made using the Cox proportional hazards
odel (time-to data), Fisher exact test (count data), and
he t test (continuous data). The Thrombolysis In Myo-
ardial Infarction (TIMI) study group has a copy of the
atabase and has independently confirmed the data pre-
Abbreviations
and Acronyms
ACS  acute coronary
syndromes
ADP  adenosine
diphosphate
CABG  coronary artery
bypass grafting
CI  confidence interval
IQR  interquartile range
NSTE-ACS  non–ST-
segment acute coronary
syndromes
PCI  percutaneous
coronary interventionented here.
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atient population. A total of 1,018 patients were
creened and provided informed consent, and 990 pa-
ients from 132 sites were randomized. After randomiza-
ion, 984 patients received at least 1 dose of study drug
nd were included in the safety analysis dataset. A total of
91 (50%) were scheduled to receive study drug for 12
eeks, 243 (25%) for 8 weeks, and 250 (25%) for 4 weeks.
he median duration of study drug treatment was 56
ays.
The mean age of patients enrolled was 63 years (range 30
o 93 years), more than a third of were women, 24% had
iabetes mellitus, and 48% had ST-segment depression
0.5 mm and 62% were coded as non–ST-segment eleva-
ion MI (Table 1). Ninety-eight percent of patients received
spirin, 85% received heparin (51% unfractionated heparin,
0% low-molecular-weight heparin, not mutually exclu-
ive), 31% received glycoprotein IIb/IIIa inhibitors, 85%
eceived beta-blockers, and 86% received statins, without
ifferences between the treatment groups. A total of 67% of
atients underwent coronary angiography, 42% had PCI
2% balloon angioplasty, 40% stenting, of which 48% had
aseline Characteristics in the Primary Safety Cohort
Table 1 Baseline Characteristics in the Primary Safety Cohort
Clopidogrel 75 mg
Daily (n  327)
Age, yrs (mean  SD) 62 11.0
Men, n (%) 217 (66)
White race, n (%) 308 (94)
Diabetes, n (%) 81 (25)
Prior MI, n (%) 91 (28)
Prior PCI, n (%) 56 (17)
Prior CABG, n (%) 36 (11)
Weight, kg (mean  SD) 83 16.5
Body mass index, kg/m2 (mean  SD) 29 5.0
Prior clopidogrel, n (%) 92 (28)
tatistical testing done with analysis of variance for age, weight, body mass index, and Fisher exa
CABG  coronary artery bypass grafting; MI  myocardial infarction; PCI  percutaneous coron
leeding Events: Number of Events and Kaplan-Meier Event Rates
Table 2 Bleeding Events: Number of Events and Kaplan-Meier E
Clopidogrel 75 mg
Daily (n  327)
AZD614
Twice Dail
Through week 4
Total 26 (8.1) 32 (
Major 22 (6.9) 23 (
Major—fatal/life-threatening 14 (4.4) 11 (
Major—other 8 (2.5) 12 (
Minor 4 (1.3) 9 (
Through week 12
Total 30 (9.9) 34 (
Major 26 (8.7) 26 (
Major—fatal/life-threatening 16 (5.4) 13 (
Major—other 10 (3.3) 13 (
Minor 4 (1.3) 9 (alues are n (%). Total bleeding is defined as major or minor bleeding. The number of events to the 2 time
rom 4 to 12 weeks, incidence rates and Kaplan-Meier event rates will differ. Statistical testing done usinrug-eluting stents), and 9% underwent post-randomization
oronary artery bypass grafting (CABG). The median time to
CI was 20 h after randomization (interquartile range [IQR]
2 to 72 h), and the median time to CABG was 10 days after
andomization (IQR 7 to 19 days).
rimary end point. The Kaplan-Meier rate of the primary
nd point, protocol-defined major or minor bleeding at 4
eeks, was not different among the 3 groups, with 26
atients (8.1%) experiencing a bleeding episode in the
lopidogrel group, compared with 32 (9.8%) in the
ZD6140 90-mg group and 25 (8.0%) in the 180-mg
roup (p  0.43 and p  0.96 vs. clopidogrel, respectively)
Table 2). The rates of “major—fatal/life-threatening”
leeding and “major—other” bleeding were not different
mong the AZD6140 and clopidogrel groups (Fig. 1).
here were 2 fatal bleeds, both in the AZD6140 90-mg
roup. Protocol-defined minor bleeding occurred in 4 pa-
ients (1.3%) in the clopidogrel group, 9 (2.7%) in the
ZD6140 90-mg group, and 12 (3.8%) in the AZD6140
80-mg group over 4 weeks (p  0.18 and p  0.05 vs.
lopidogrel, respectively). A similar pattern of bleeding was
een up through 12 weeks.
AZD6140 90 mg
ice Daily (n  334)
AZD6140 180 mg
Twice Daily (n  323)
p Value
(Global)
64 12.1 63 11.4 0.20
204 (61) 211 (65) 0.33
316 (95) 305 (94) 0.98
83 (25) 77 (24) 0.95
81 (24) 78 (24) 0.48
43 (13) 51 (16) 0.29
28 (8) 26 (8) 0.36
81 17.0 81 16.4 0.27
28 5.4 29 5.1 0.72
87 (26) 86 (27) 0.83
for all other variables.
ervention.
Rates
mg
334)
p Value vs.
Clopidogrel
AZD6140 180 mg
Twice Daily (n  323)
p Value vs.
Clopidogrel
0.43 25 (8.0) 0.96
0.91 16 (5.1) 0.35
0.53 10 (3.2) 0.44
0.38 6 (1.9) 0.61
0.18 12 (3.8) 0.0504
0.62 33 (11.4) 0.72
0.96 20 (6.3) 0.32
0.55 14 (4.3) 0.61
0.54 6 (1.9) 0.34
0.18 16 (6.1) 0.01Twvent
0 90
y (n 
9.8)
7.1)
3.4)
3.7)
2.7)
10.9)
8.6)
4.5)
4.2)
2.7)points is given with a Kaplan-Meier percent estimate of the event rate. Because follow-up ranged
g a Cox proportional hazards model.
l
S
w
A
i
7
1
d
p
g
t
2
A
1
3
(
c
i
t
c
s
i
2
1
d
(
p
r
t
d
h
1
a
w
A
a
c
c
B
f
r
d
t
w
i
A
t
i
K
s
d
t
1847JACC Vol. 50, No. 19, 2007 Cannon et al.
November 6, 2007:1844–51 The DISPERSE-2 TrialThe most common type of bleeding was epistaxis, fol-
owed by periprocedural hemorrhage or hematoma.
eventy-three percent of all bleeds in the clopidogrel group
ere procedure related versus 53% and 52% in the
ZD6140 90- and 180-mg groups, respectively. Gastro-
ntestinal bleeding occurred in 3 clopidogrel patients (0.9%),
AZD6140 90-mg patients (2.1%), and 4 AZD6140
80-mg patients (1.2%). Bleeding episodes that led to
iscontinuation of study treatment occurred in 3 clopidogrel
atients (0.9%), 8 patients (2.4%) in the AZD6140 90-mg
roup, and 5 (1.5%) in the AZD6140 180-mg group. For
he entire study period, blood transfusions were required by
2 patients (6.7%) in the clopidogrel group, 24 (7.2%) in the
ZD6140 90-mg group, and 15 (4.6%) in the AZD6140
80-mg group; the median number of units transfused was
(IQR 2 to 4 U). Protocol-defined minimal bleeding
nonadjudicated) occurred in 70 (21%) patients in the
lopidogrel group and in 89 (27%) and 100 (31%) patients
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Figure 1 Rates of Major or Minor Bleeding Through 4 Weeks
Rates of bleeding at week 4 (primary end point, A) and overall in the trial (B).
The percentages given at the top of the bar graphs are the rates of total bleed-
ing, defined as major or minor. *Minor bleeding without major bleeding. bid 
twice a day; qd  once a day.n the AZD6140 90- and 180-mg groups, respectively, overhe entire study period (p  0.12 and p  0.006, vs.
lopidogrel, respectively).
Assessment of bleeding by AZD6140 loading dose
howed that major bleeding within the first 48 h occurred
n 8 clopidogrel patients (2.4%), compared with 3 (1.8%),
(1.3%), and 6 (1.8%) patients in the AZD6140 90-,
80-, and 270-mg groups, respectively (Fig. 2). Protocol-
efined minor bleeding within the first 48 h occurred in 1
0.3%) clopidogrel patient and in 1 (0.6%), 0, and 6 (1.8%)
atients in the AZD6140 90-, 180-, and 270-mg groups,
espectively.
Among the 84 patients who underwent CABG, median
imes (IQRs) to the procedure from the last dose of study
rug were 96 (40 to 168), 55 (30 to 124), and 60 (29 to 144)
in the clopidogrel, AZD6140 90-mg, and AZD6140
80-mg groups, respectively. One of 2 clopidogrel patients
nd 5 of 10 AZD6140 patients who underwent CABG
ithin 1 day of receiving study drug had a major bleed.
mong those undergoing CABG between 1 and 5 days
fter the last dose, the rate of major bleeding was numeri-
ally lower in the AZD6140 group (10 of 28 patients; 36%),
ompared with the clopidogrel group (9 of 14; 64%).
eyond 5 days, the rate of major bleeding was 60% (6 of 10)
or clopidogrel patients and 50% (10 of 20) for AZD6140
ecipients.
The rates of death or cardiovascular death were not
ifferent among groups (Table 3). There was a numerical
rend toward lower rates of MI in the AZD6140 groups,
ith 15 (5.6%) patients in the clopidogrel group, 12 (3.8%)
n the AZD6140 90-mg group, and 8 (2.5%) in the
ZD6140 180-mg group experiencing an MI. The respec-
ive hazard ratios were 0.80 and 0.53, with confidence
ntervals (CIs) of 0.37 to 1.70 and 0.23 to 1.25. The
aplan-Meier event rate of cardiovascular death, MI, or
troke, the combined end point used in the CURE (Clopi-
ogrel in Unstable angina to prevent Recurrent Events)
rial, showed similar rates between clopidogrel (6.2%) and
Figure 2 Rates of Major or Minor
Bleeding Within 48 h of Randomization
The percentages given at the top of the bar graphs are the rates of total bleed-
ing, defined as major or minor. *Minor bleeding without major bleeding; †load-
ing dose. Abbreviations as in Figure 1.
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The DISPERSE-2 Trial November 6, 2007:1844–51ZD6140 90-mg (6.0%) but a numerically lower rate of
.5% in the AZD6140 180-mg group, with a hazard ratio of
.65 and a 95% CI of 0.30 to 1.38 (Fig. 3). Rates of
eriprocedural MI were 1.5% for the clopidogrel group and
.1% and 0.9% for the AZD6140 90- and 180-mg groups,
espectively. This accounted for 43% of the overall number
f MI and was similar in each of the groups. No silent MIs
r CABG-associated MIs were reported. After discontinu-
tion of study medication, the number of major cardiovas-
ular events in the clopidogrel, AZD6140 90- and 180-mg
roups were 5, 12, and 6, respectively. The numbers of
ardiovascular deaths were 1, 6, and 3, and MIs were 3, 3,
nd 2, respectively.
Table 4 lists crude incidence rates of other investigator-
eported adverse events. Nonspecific factors, such as head-
che, were common. There appeared to be a higher rate
f nausea, dyspepsia, and hypotension reported among
ZD6140 recipients. Dyspnea was more common in the
ZD6140 groups (Table 4). Of those who reported dys-
nea, 27% of the patients had resolution of this symptom
ithin 24 h, 25% had resolution of the dyspnea after 24 h,
nd 48% experienced persistent symptoms during treatment
15 days). The overall incidence of persistent dyspnea was
pproximately 2% for clopidogrel, and 6% for each of the
ZD6140 groups. Discontinuation rates were low and
imilar between groups: 6% of patients receiving AZD6140
0 mg twice a day, 7% of patients receiving AZD6140 180
g twice a day, and 6% of patients receiving clopidogrel 75
g once a day.
Table 5 presents the results of the arrhythmia analysis
rom 885 patients (89.4% of all patients enrolled). There
as no difference in the rates of ventricular tachycardias
mong the 3 treatment groups. However, there were a
linical End Points: Number of Events and Kaplan-Meier Event Rate
Table 3 Clinical End Points: Number of Events and Kaplan-Meie
End Point, %
Clopidogrel 75 mg
Daily (n  327)
AZD6140 90
Twice Daily (n 
Through 4 weeks, n (%)
All-cause death 2 (0.6) 6 (1.9)
CV death 2 (0.6) 6 (1.9)
MI 11 (3.5) 7 (2.2)
Stroke 1 (0.3) 2 (0.6)
SRI 2 (0.6) 2 (0.6)
RI 5 (1.6) 10 (3.2)
CV death/MI/stroke 12 (3.8) 14 (4.3)
Through 12 weeks, n (%)
All-cause death 4 (1.3) 7 (2.4)
CV death 4 (1.3) 6 (1.9)
MI 15 (5.6) 12 (3.8)
Stroke 1 (0.3) 2 (0.6)
SRI 3 (1.4) 5 (2.3)
RI 9 (3.0) 13 (4.9)
CV death/MI/stroke 17 (6.2) 19 (6.0)
one of these rates were statistically significantly different between the treatment groups. The nu
ollow-up ranged from 4 to 12 weeks, incidence rates and Kaplan-Meier event rates will differ. Sta
CV  cardiovascular; MI  myocardial infarction; RI  recurrent ischemia; SRI  severe recurrreater number of mostly asymptomatic ventricular pausesA
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Clopidogrel 75 mg daily
0
5%
10%
15%
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Study Day
Study Day
1 11 21 31 41 51 61 71 81 91
0
5%
10%
15%
Figure 3 Kaplan-Meier Estimates of Clinical End Points
Cumulative risk of (A) composite clinical end point (cardiovascular death, myocar-
dial infarction, or stroke), and (B) myocardial infarction events. bid  twice a day.s
r Event Rates
mg
334)
p Value vs.
Clopidogrel
AZD6140 180 mg
Twice Daily (n  329)
p Value vs.
Clopidogrel
0.18 3 (1.0) 0.64
0.18 3 (1.0) 0.64
0.34 3 (1.0) 0.047
0.57 0 (0.0) 0.99
0.99 4 (1.3) 0.41
0.21 4 (1.6) 0.98
0.71 6 (1.9) 0.17
0.38 6 (1.7) 0.72
0.54 6 (1.7) 0.72
0.41 8 (2.5) 0.06
0.57 0 (0.0) 0.99
0.50 9 (3.7) 0.09
0.29 9 (3.4) 0.78
0.90 11 (3.5) 0.12
mber of events to the 2 time points is given, with a Kaplan-Meier % estimate of the event rate. Because
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November 6, 2007:1844–51 The DISPERSE-2 Trialasting 2.5 s detected post hoc among patients receiving
ZD6140 compared with those receiving clopidogrel. Of
he patients who experienced pauses 5 s, 7 were due to
inus block or sinus node exit block and 4 were due to
omplete heart block.
iscussion
his trial evaluated the first reversible oral ADP antagonist,
ZD6140, in a patient population with ACS. As reported
n the DISPERSE-2 substudy companion paper (13), the
oses tested yielded a level of platelet inhibition that was
early double that of clopidogrel, indicating that more
ffective P2Y12 inhibition is feasible. With respect to the
rimary objective of assessing the overall safety and tolera-
ility of AZD6140, the current study demonstrated no
ignificant difference, despite the higher level of platelet
nhibition, between this agent and clopidogrel in the rate of
rotocol-defined major bleeding (which is similar to the
efinition of TIMI major or minor bleeding). Slightly more
rotocol-defined minor bleeding was observed in the
ZD6140 groups, but with numerically lower rates of major
leeding. Thus, the rate of overall protocol-defined major or
inor bleeding was not different among the AZD6140 and
rude Incidence Rates of Investigator-Reported Adverse Events
Table 4 Crude Incidence Rates of Investigator-Reported Advers
Clopidogrel 75 mg
Daily (n  327)
AZD6140 90 mg
Twice Daily (n  334)
Dyspnea 21 (6.4) 35 (10.5)
Chest pain 29 (8.9) 25 (7.5)
Headache 28 (8.6) 32 (9.6)
Nausea 11 (3.4) 22 (6.6)
Dyspepsia 9 (2.8) 16 (4.8)
Insomnia 9 (2.8) 18 (5.4)
Diarrhea 11 (3.4) 10 (3.0)
Hypotension 2 (0.6) 4 (1.2)
Dizziness 10 (3.1) 14 (4.2)
Syncope 2 (0.6) 4 (1.2)
Rash 2 (0.6) 3 (0.9)
he rates are crude incidences of number of patients with reported events divided by the total num
esting done with Fisher exact test.
rrhythmia Events Detected on Continuous ECG Monitoring Begun
Table 5 Arrhythmia Events Detected on Continuous ECG Monit
Clopidogrel 75 mg
Once Daily
n  297, n (%)
VTs
Patients with sustained VT 30 s 1 (0.3)
Patients with at least 1 NSVT 65 (22%)
Patients with at least 1 triplet 93 (31%)
Ventricular pauses
Patients with at least 1 pause 2.5 s 13 (4.3%)
Patients with 3 episodes of pauses 2.5 s 1 (0.3%)
Patients with at least 1 pause 5 s 1 (0.3%)
p values calculated with Fisher exact test. The first compares AZD6140 90 mg versus clopidogre
ustained VT (lasting 30 s), nonsustained ventricular tachycardia (NSVT) (4 beats and 30 s in
ause that results in the absence of a QRS complex that lasts for 2.5 s.
ECG  electrocardiogram.lopidogrel groups. The bleeding rates also were not differ-
nt among patients who had or had not previously received
lopidogrel or among those who did or did not receive a
oading dose of AZD6140 or did or did not receive
lycoprotein IIb/IIIa inhibitors. Thus, in this initial expe-
ience, it appears that the higher level of inhibition of P2Y12
s reasonably well tolerated, even in the face of multiple
dditional antithrombotic agents and with invasive proce-
ures being performed in more than two-thirds of patients.
There was an intriguing, numerically lower rate of bleed-
ng in AZD6140-treated patients undergoing CABG be-
ween 1 and 5 days after stopping study drug, which would
e consistent with a recovery of platelet function due to the
eversible binding of AZD6140 to the P2Y12 receptor.
owever, further study in a larger number of patients is
eeded to confirm such a benefit with this agent, compared
ith the nonreversible effects of clopidogrel (or other
hienopyridines). If these results were confirmed, however,
he use of the reversible agent AZD6140, with a half-life of
2 h, would allow greater flexibility for use of P2Y12
nhibitors. One could treat all patients at the time of
resentation with ACS, but stop the treatment for patients
ho are found on coronary angiography to need CABG.
ents
p Value vs.
Clopidogrel
AZD6140 180 mg
Twice Daily (n  323)
p Value vs.
Clopidogrel
0.07 51 (15.8) 0.0002
0.57 24 (7.4) 0.57
0.69 21 (6.5) 0.37
0.07 21 (6.5) 0.07
0.22 10 (3.1) 0.82
0.12 15 (4.6) 0.22
0.83 24 (7.4) 0.02
0.004 12 (3.7) 0.01
0.53 11 (3.4) 0.83
0.69 5 (1.5) 0.28
1.00 6 (1.9) 0.17
atients in the safety cohort. Median exposure of patients was approximately 2 months. Statistical
andomization
Begun at Randomization
AZD6140 90 mg
Twice Daily
n  305, n (%)
AZD6140 180 mg
Twice Daily
n  283, n (%) p Values*
0 (0.0) 1 (0.3) 0.49, 1.00
67 (22%) 74 (26%) 1.00, 0.24
89 (29%) 77 (27%) 0.59, 0.32
17 (5.5%) 28 (9.9%) 0.58, 0.014
6 (2.0%) 14 (4.9%) 0.12,0.001
5 (1.6%) 6 (2.1%) 0.22, 0.06
e second AZD6140 180 mg versus clopidogrel. Ventricular tachycardia (VT) was categorized into
), and triplets (3 ventricular beats). A ventricular pause was defined as either sinus or ventriculare Evat R
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The DISPERSE-2 Trial November 6, 2007:1844–51his would avoid the need to make patients wait 5 days for
ABG, as recommended in current American College of
ardiology/American Heart Association guidelines and
upported by recent studies (14–16). Similarly, for patients
reated chronically post-ACS, it would potentially allow
reater flexibility for other types of elective surgery.
There were not sufficient numbers of clinical events to
eliably determine the efficacy of AZD6140 versus clopi-
ogrel. The overall rates of clinical events, however, were
onsistent with prior ACS trials, and there was an apparent
ose-response in the MI rate among AZD6140 recipients,
ith the highest rate being observed among patients treated
ith clopidogrel, and lower rates among those who had
eceived the 90- and 180-mg doses of AZD6140. The
verall composite rate of cardiovascular death, MI, or stroke
ppeared to be numerically lower only at the higher dose,
ut the CIs for these clinical events are wide, and thus a
arge phase III trial (which is ongoing) will be required to
valuate the true efficacy of this agent. It is notable,
owever, that the benefit of AZD6140 in preventing MI
ppeared to be present both surrounding the time of PCI
nd also during the 1- to 3-month follow-up period, with
7% of the MIs being spontaneous in this study.
Judging by the rate of discontinuation of (blinded) study
edication, the overall tolerability of AZD6140 was good,
ith a similar percentage of patients discontinuing study
edication in each of the 3 groups. There were differences
n the adverse events reported between drugs, however, with
igher incidences of dyspnea, hypotension, and nausea
mong AZD6140 recipients. There also was a mild increase
n uric acid levels with AZD6140. The number of patients
ho discontinued study treatment due to these reported side
ffects, however, was small (1% to 4% overall). Nonetheless,
his observation highlights the fact that each new class of
rugs has the potential for specific side effects. Thrombo-
ytopenia or neutropenia was not observed with either
ZD6140 or clopidogrel in this study.
The present study confirmed the dose-dependent in-
rease in reported dyspnea in the AZD6140 groups as first
eported in the DISPERSE study, but also reports a rate of
yspnea in the clopidogrel group. As in the DISPERSE
tudy (12), the episodes were reported as mild or moderate
n severity, were often self-limited, and rarely led to study
rug discontinuation. There were not reported signs of fluid
etention, congestive heart failure, or bronchospasm in the
ases of AZD6140-related dyspnea, suggesting it does not
elate to heart failure. Investigations are ongoing to deter-
ine if any physiologic basis might exist for this finding.
The greater number of mostly asymptomatic ventricular
auses detected post hoc in patients receiving AZD6140
as both unexpected and not previously reported in studies
f AZD610. Although there is no known mechanism to
xplain this observation, it is possible that AZD6140, although
tself not an ATP or adenosine analog, may affect adenosine
etabolism. Several agents, such as dipyridamole, draflazine,
nd iodotubercidin, modulate intra- and paracellular adeno-ine concentration via interference with adenosine degrada-
ion and reuptake inhibition. If AZD6140 has similar
ctions, it is possible that the increased incidence of asymp-
omatic ventricular pauses and other observed side effects of
ZD6140 such as dyspnea and hyperuricemia may also be
ediated via modulation of adenosine metabolism (17,18).
urther assessments of the effects of AZD6140 on adeno-
ine metabolism and on cardiac conduction are required.
onclusions
his study has demonstrated that AZD6140 shows similar
afety and tolerability to clopidogrel. Because AZD6140 is
reversible inhibitor of the P2Y12 receptor, it offers the
otential for flexibility with respect to more rapid initiation
f coronary bypass and other surgical procedures after
iscontinuation of the drug. With the lack of increased
ajor bleeding and the encouraging trends in efficacy
bserved in the current study, this agent is currently
eing studied in PLATO (PLATelet inhibition and
atient Outcomes), a large outcomes trial in 18,000
atients with ACS.
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on, TIMI Study Group, Cardiovascular Division, Brigham and
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or a full list of investigators, and detailed entry criteria, definitions, and
tatistical analysis, please see the online version of this article.
